Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in advanced anal cancer
NCT04046133Phase 1Active, not recruiting
- Sponsor
- Cardiff University
- Start
- Oct 2020
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of pembrolizumab in anal squamous cell carcinoma (SCCA), sponsored by Cardiff University. Primary endpoint: Safety and tolerability. Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT04046133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046133.